The results demonstrated ViaLase FLigHT's potential as a safe and effective treatment option for primary open angle glaucoma
ViaLase FLigHT is intended for the treatment of primary open angle glaucoma. (Credit: Brands&People on Unsplash)
ViaLase has reported positive results from the first-in-human (FIH) study of femtosecond laser image-guided high-precision trabeculotomy (FLigHT) treatment carried out with the ViaLase technology.
The US-based medical technology company has designed the non-invasive laser treatment for primary open angle glaucoma (POAG).
According to ViaLase, the results validate that FLigHT is a safe and effective treatment alternative to support glaucoma patient care.
ViaLase chief medical officer Richard Lewis said: “We are encouraged by the results of this study, which validate the safety of the ViaLase technology in performing FLigHT in patients with glaucoma.
“We look forward to continuing this important research, with the ultimate goal of bringing a safe and effective noninvasive treatment to glaucoma patients, supported by a multi-centre prospective randomised trial which is currently enrolling.”
ViaLase said that the safety and effectiveness of the FLigHT treatment were evaluated in a 12-month, single-centre, non-randomised study. The study also monitored the treatment’s ability to lower intraocular pressure (IOP).
The study recruited nine patients (15 eyes) with open angle glaucoma or ocular hypertension to receive the non-incisional procedure following medication washout.
Upon completion of the trial, the investigators found a decrease in mean IOP at 12 months and with no sign of any adverse events associated with FLigHT therapy during the 12-month duration.
Additionally, 100% of the eyes did not require IOP-lowering medication, and gonioscopy at the same time point showed no signs of scarring at the treatment site after one year.
With the use of advanced imaging technology and femtosecond laser precision and accuracy, ViaLase’s FLigHT treatment offers a noninvasive procedure that may be performed by a qualified physician, ViaLase added.
The outcomes of this first-in-human trial are currently being further validated in a multicentre, randomised trial.
The clinical-stage medical technology company is engaged in the development and commercialisation of femtosecond lasers for glaucoma patients.